EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies

Bohan Wang; Yachong Liu; Zhibin Liao; Haofeng Wu; Bixiang Zhang; Lei Zhang

doi:10.1186/s40164-023-00405-2

EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies

Exp Hematol Oncol. 2023 Jun 2;12(1):52. doi: 10.1186/s40164-023-00405-2.

Authors

Bohan Wang^#¹, Yachong Liu^#¹, Zhibin Liao¹, Haofeng Wu¹, Bixiang Zhang², Lei Zhang^{3

4

5}

Affiliations

¹ Hepatic Surgery Center, Institute of Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
² Hepatic Surgery Center, Institute of Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. bixiangzhang@163.com.
³ Hepatic Surgery Center, Institute of Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. zhangl@tjh.tjmu.edu.cn.
⁴ Department of Hepatobiliary Surgery, Shanxi Tongji Hospital, Tongji Medical College, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Shanxi Medical University, Huazhong University of Science and Technology, Taiyuan, 030032, China. zhangl@tjh.tjmu.edu.cn.
⁵ Key Laboratory of Hepatobiliary and Pancreatic Diseases of Shanxi Province (Preparatory), Shanxi Tongji Hospital, Tongji Medical College, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Shanxi Medical University, Huazhong University of Science and Technology, Taiyuan, 030032, China. zhangl@tjh.tjmu.edu.cn.

^# Contributed equally.

Abstract

Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death. The accumulation of genetic and epigenetic changes is closely related to the occurrence and development of HCC. Enhancer of zeste homolog 2 (EZH2, a histone methyltransferase) is suggested to be one of the principal factors that mediates oncogenesis by acting as a driver of epigenetic alternation. Recent studies show that EZH2 is widely involved in proliferation and metastasis of HCC cells. In this review, the functions of EZH2 in HCC progression, the role of EZH2 in tumor immunity and the application of EZH2-related inhibitors in HCC therapy are summarized.

Keywords: EZH2; EZH2 inhibitor; HCC; Immunity.

Publication types

Review

Abstract

Publication types

Grants and funding